Shots:
- BioAtla has shared ongoing P-I dose-escalation trial data on BA3182 for treatment-refractory metastatic adenocarcinoma at ESMO 2025
- As of June 20, 2025, 39 pts received BA3182 (QW) in the range of 0.0026 to 0.6mg with either 0, 1, or 2 priming doses, 4–7 days before treatment; 17 received IV doses (0.0026–0.032mg) & 22 received SC doses (0.032–0.6mg)
- In the trial, 5 pts achieved objective tumor reductions: CRC (-8% & -10%), breast adenocarcinoma (-11%), cholangiocarcinoma (-13%), & NSCLC (-25%), plus prolonged PFS of 11 & 14mos. was seen in 2 CRC pts. SC dosing showed delayed & lower peak concentrations with comparable trough levels to IV. Dose escalation continues at 1.2mg flat, with updated P-I data expected in H2’25
Ref: Globenewswire | Image: BioAtla | Press Release
Related News:- Vertex Presents Long-Term CLIMB Trial Program Data of Casgevy (Exagamglogene Autotemcel) to Treat Hemoglobinopathies at EHA 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
